Document Detail


Signaling effectors underlying pathologic growth and remodeling of the heart.
MedLine Citation:
PMID:  23281408     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Cardiovascular disease is the number one cause of mortality in the Western world. The heart responds to many cardiopathological conditions with hypertrophic growth by enlarging individual myocytes to augment cardiac pump function and decrease ventricular wall tension. Initially, such cardiac hypertrophic growth is often compensatory, but as time progresses these changes become maladaptive. Cardiac hypertrophy is the strongest predictor for the development of heart failure, arrhythmia, and sudden death. Here we discuss therapeutic avenues emerging from molecular and genetic studies of cardiovascular disease in animal models. The majority of these are based on intracellular signaling pathways considered central to pathologic cardiac remodeling and hypertrophy, which then leads to heart failure. We focus our discussion on selected therapeutic targets that have more recently emerged and have a tangible translational potential given the available pharmacologic agents that could be readily evaluated in human clinical trials.
Authors:
Jop H van Berlo; Marjorie Maillet; Jeffery D Molkentin
Related Documents :
24675088 - An integrated characterisation of serological, pathological and functional events in do...
23493668 - The cardiomyocyte as a source of cytokines in cardiac injury.
19840558 - The chemokine network in relation to infarct size and left ventricular remodeling follo...
10642758 - Ad hoc coronary intervention.
9152488 - Collagen synthesis is upregulated in mitral valves subjected to altered stress.
2331998 - Vagal heart rate control after percutaneous transluminal coronary angioplasty.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review     Date:  2013-01-02
Journal Detail:
Title:  The Journal of clinical investigation     Volume:  123     ISSN:  1558-8238     ISO Abbreviation:  J. Clin. Invest.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-01-02     Completed Date:  2013-03-11     Revised Date:  2014-01-09    
Medline Journal Info:
Nlm Unique ID:  7802877     Medline TA:  J Clin Invest     Country:  United States    
Other Details:
Languages:  eng     Pagination:  37-45     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Arrhythmias, Cardiac / drug therapy,  etiology,  metabolism,  mortality,  pathology,  physiopathology
Cardiomegaly / complications,  drug therapy*,  metabolism*,  mortality,  pathology,  physiopathology
Clinical Trials as Topic
Death, Sudden / epidemiology
Disease Models, Animal
Heart Failure / drug therapy,  etiology,  metabolism,  mortality,  pathology,  physiopathology
Humans
Signal Transduction*
Ventricular Remodeling*
Grant Support
ID/Acronym/Agency:
//Howard Hughes Medical Institute
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Adaptive immunity in atherogenesis: new insights and therapeutic approaches.
Next Document:  Calcium cycling proteins and heart failure: mechanisms and therapeutics.